Click below to listen to audio of Prof. John Seymour (Peter MacCallum Cancer Centre) interviewing Prof. Arnon Kater (Amsterdam University Medical Centre) about the current CLL treatment landscape.
Prof. Seymour and Prof. Kater discuss the various therapies now available to treat CLL, and how toxicities, comorbidities and the patient’s genetic risk profile affect their decision when choosing between these therapies.
Disclaimer: Thanks for listening to this Educational podcast, initiated and sponsored by AbbVie Pty Ltd (“AbbVie”). The individual opinions expressed within the podcast may not represent the views of AbbVie. AbbVie does not endorse the use of unregistered products or products outside their registered indications. Please refer to the Australian product information for licensed instructions. For references supporting the discussions in these podcasts please see below. For more information, contact medinfoanz@abbvie.com or call 1800 043 460 in Australia. Podcast ID AU-VENC-230069. May 2023. Copyright AbbVie Pty Ltd, Mascot NSW 2023.
Contact
Discover more about how we can help you in your practice.
PBS Information
Venclexta: VENCLEXTA (venetoclax) in combination with rituximab is PBS listed for relapsed or refractory chronic lymphocytic leukaemia (CLL). VENCLEXTA in combination with obinutuzumab is PBS listed for first line treatment of CLL or small lymphocytic lymphoma (SLL). VENCLEXTA in combination with azacitidine is PBS listed for treatment of acute myeloid leukaemia (AML). General Schedule listing. Authority required (telephone). Refer to PBS schedule for full authority information. VENCLEXTA monotherapy is not listed on the PBS. VENCLEXTA in combination with low-dose cytarabine is not listed on the PBS for treatment of AML.
Please review the full Product Information (PI) before prescribing, available below.
References:
1. Seymour JF et al. N Engl J Med 2018; 378(12): 1107–20. 2. Seymour JF et al. Blood 2022; 140(8): 839–850. 3. Goede V et al. Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucil in patients with chronic lymphocytic leukemia and comorbidities: final survival analysis of the CLL11 study. Abstract presented at EHA 2018. 4. Laribi K et al. Hemasphere 2022; 6(6): e716. 5. Mato AR et al. Clin Cancer Res 2020; 26(14): 3589–96. 6. Mato AR et al. Haematologica 2018; 103(5): 874–9. 7. Byrd J et al. N Engl J Med 2014; 371(3): 213–23. 8. O’Brien SM et al. Blood 2016; 128(22): 233.
AU-VENC-230069 Last revised September 2023